{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-015282","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2025-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.569191+00:00","generated_at":"2026-05-19T07:06:15.912429+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FibroBiologics closes $5M third tranche of $25M SEPA with Yorkville; funds for R&D and diabetic foot ulcer trial","bullets":["Third $5M tranche of $15M pre-paid advance drawn; total $15M now under SEPA with YA II PN, Ltd.","Convertible promissory note: 0% interest (18% on default), matures Dec 20, 2025, convertible at lower of $0.9801 or 94% of 5-day VWAP.","Proceeds for general corporate purposes, including R&D and Phase 1/2 diabetic foot ulcer trial expected H2 2025.","Company may sell additional $10M common stock to Yorkville with consent while notes outstanding.","Conversion limited to 4.99% beneficial ownership cap; prior conversions totaled $5.7M principal at varying prices."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-015282","json":"https://secwatch.observer/filing/0001641172-25-015282.json","markdown":"https://secwatch.observer/filing/0001641172-25-015282.md","text":"https://secwatch.observer/filing/0001641172-25-015282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000164117225015282/0001641172-25-015282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000164117225015282/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T07:06:15.912429+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4cacfec9d2b17cd262a29015797225f31778ff2b","claim":"FibroBiologics, Inc. incurred convertible notes of $5 million with YA II PN, Ltd. at 0% maturing December 20, 2025.","evidence_excerpt":"The third tranche of the Pre-Paid Advance was disbursed on June 16, 2025 (the “Third Closing”) in the principal amount of $5 million and evidenced by a convertible promissory note (the “Third Promissory Note).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000164117225015282/0001641172-25-015282-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$5 million"},{"label":"Counterparty","value":"YA II PN, Ltd."},{"label":"Rate","value":"0%"},{"label":"Maturity","value":"December 20, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}